Overview

Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC

Status:
NOT_YET_RECRUITING

Trial end date:
2033-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this trial is to learn more about the effects of AAA602 and AAA802 in men with prostate-specific membrane antigen (PSMA) positive high-risk localized prostate cancer (HRLPC) before surgery to remove the prostate and lymph nodes present in the pelvis area. Lymph nodes are small structures near the prostate that help fight infections. These lymph nodes are removed during surgery because they are a site the disease can spread to.

Phase:

PHASE1

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

Actinium-225
gallium 68 PSMA-11
Lutetium-177